Ultrasound and light therapies to investigate targeted treatment of Parkinson’s disease

A groundbreaking study by scientists at Nottingham Trent University will explore the use of ultrasound and light therapies to investigate targeted treatments for Alzheimer’s disease, dementia, and Parkinson’s disease. This first-of-its-kind research aims to determine whether treatment can be delivered to the brain using specialized microbubbles. The team hopes to revolutionize how these neurodegenerative diseases are treated by harnessing non-invasive techniques to bypass the body’s natural barriers. One of the primary challenges in treating these conditions is the blood-brain barrier, a protective shield that prevents harmful substances from reaching the brain. Unfortunately, this barrier also blocks potential treatments from passing through. Researchers at Nottingham Trent University believe that, when combined with ultrasound, these microbubbles could temporarily open the blood-brain barrier, allowing medications or stem cell therapies to enter the brain and directly target damaged areas. This could lead to the repair or reversal of the damage caused by Alzheimer’s, Parkinson’s, and dementia. Dr. Gareth Cave, head of the nanoscience and drug delivery group in NTU’s School of Science and Technology, expressed optimism about the potential of this novel approach. "We believe the cure for Alzheimer’s, Parkinson’s, and dementia could lie in the use of non-invasive techniques and natural materials," he said. "By harnessing knowledge spanning a range of fields, we are pursuing a totally different and truly innovative approach." The researchers are also investigating the possibility of using light particles to boost the energy of brain cells and the blood-brain barrier, enabling them to heal more effectively and quickly. This approach, coupled with the use of MRI to monitor the physiological effects of ultrasound in real-time, could allow for a highly precise and controlled method of treatment. Dr. Cave underscored the importance of this research in the context of the emotional and personal toll these diseases take: "These illnesses do not discriminate, and once they take hold, they rob people of the ones they love most and valuable years together." As part of the project, the team is developing a laboratory model of a 3D blood-brain barrier using human brain cell cultures. This model will allow researchers to rapidly and effectively screen potential therapeutic targets, accelerating the discovery of treatments that could improve the lives of millions of people worldwide. Data suggests that over 944,000 people in the UK currently live with dementia, a number expected to rise to more than one million by 2030 due to the aging population. This research, funded by over £1 million from the Eranda Rothschild Foundation, aims to develop new therapies that could slow or even reverse the progression of neurodegenerative diseases, offering hope to countless individuals and families affected by these debilitating conditions. The study represents a major step forward in the fight against Alzheimer’s, Parkinson’s, and dementia, offering a vision of the future where non-invasive, effective treatments are within reach. With continued innovation and support, this research could lead to transformative therapies that not only improve quality of life but also extend the time patients can spend with their loved ones.